← All trials
NCT03647774
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2018
- Primary completion
- Aug 31, 2023
- Completion date
- Dec 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oslo Metropolitan UniversityLead sponsor
- The Hospital of VestfoldCollaborator
- Oslo Metropolitan UniversitySponsor investigator
- Oslo Metropolitan UniversityOverall official - principal investigator
- University of BergenCollaborator
- Hospital of Southern Norway TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.